Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer

References

• Rocha Lima CM, Centeno B. Update on pancreatic cancer. Curr Opin Oncol. 2002;14(4):424–430.
   Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.
   PubMed Web of Science ®Google Scholar
• Bramhall S, Dunn JA, Neoptolemos JP. Epidemiology of pancreatic cancer. In: Beger HG, Warshaw AL, Buchler MW, et al. editors. The Pancreas. Cambridge, MA: Blackwell Science, Inc., 1998.
   Google Scholar
• Goldstein D, Carroll S, Apte M, et al. Modern management of pancreatic carcinoma. Intern Med J. 2004;34(8):475–481.
   Web of Science ®Google Scholar
• Heinemann V Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol. 2002;29(1 Suppl 3):25–35.
   Google Scholar
• McGinn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer. 2002;95(4 Suppl):933–940.
   Web of Science ®Google Scholar
• Oettle H, Riess H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer. 2002;95(4 Suppl):912–922.
   Web of Science ®Google Scholar
• Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999; 17(7): 2208–2212.
   PubMed Web of Science ®Google Scholar
• Wolff RA. Novel therapies for pancreatic cancer. Cancer J. 2001;7(4):349–358.
   Web of Science ®Google Scholar
• Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15(6):2403–2413.
   PubMed Web of Science ®Google Scholar
• Ozawa F, Friess H, Tempia-Caliera A, et al. Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen. 2001;21(1):27–44.
   Google Scholar
• Reddy SA. Signaling pathways in pancreatic cancer. Cancer J. 2001;7(4):274–286.
   Web of Science ®Google Scholar
• Shi X, Friess H, Kleeff J, et al. Pancreatic cancer: factors regulating tumor development, maintenance and metastasis. Pancreatology. 2001;1(5):517–524.
   Web of Science ®Google Scholar
• Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev. 2002;38(3):351–376.
   PubMedGoogle Scholar
• Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol. 1999;14(3):577–584.
   Web of Science ®Google Scholar
• Zagon IS, Smith JP, Conter R, et al. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma. Int J Mol Med. 2000;5(1):77–84.
   Web of Science ®Google Scholar
• Zagon IS, Hytrek SD, Smith JP, et al. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice. Cancer Lett. 1997;112(2):167–175.
   PubMed Web of Science ®Google Scholar
• Zagon IS, Roesener CD, Verderame MF, et al. Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol. 2000;17(5): 1053–1061.
   Web of Science ®Google Scholar
• Zagon IS, Ruth TB, Leure-duPree AE, et al. Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res. 2003;967(1–2):37–47.
   PubMed Web of Science ®Google Scholar
• Zagon IS, Verderame MF, Allen SS, et al. Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans. Brain Res. 2000;856(1–2):75–83.
   Web of Science ®Google Scholar
• Smith JP, Conter RL, Bingaman SI, et al. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs. 2004;15(3):203–209.
   Web of Science ®Google Scholar
• Karnofsky DA, Abelmann WH, Craver LF, et al. Performance status in cancer patients. Cancer. 1948;1:634–656.
   Web of Science ®Google Scholar
• Bergner M. Development, testing, and the use of the Sickness Impact Profile. In: Walker SR, Rosser RM, editors. Quality of Life: Assessment and Application. Boston, MA: MTP Press Limited, 1987.
   Google Scholar
• Beck AT, Ward CH, Medelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571.
   PubMed Web of Science ®Google Scholar
• Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1(3):277–299.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer Therapy Evaluation Program: Common toxicity criteria. Version 2.0 DCTD. 3–23–1998. Bethesda, MD: National Cancer Institute, National Institutes of Health; 1998.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 8–9–2006. Bethesda, MD: National Cancer Institute, National Institutes of Health; 2006.
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997;33(Suppl 1):S18–S22.
   Google Scholar
• Crippa S, Dominguez I, Rodriguez JR, et al. Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg. 2008;12(5):783–793.
   Web of Science ®Google Scholar
• Green MR. Gemcitabine safety overview. Semin Oncol. 1996;23(5 Suppl 10):32–35.
   PubMed Web of Science ®Google Scholar
• Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34(l):39–43.
   Google Scholar
• Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2002;20(1):160–164.
   PubMed Web of Science ®Google Scholar
• Sack GH Jr, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977;56(1):1–37.
   PubMed Web of Science ®Google Scholar
• Stein PD, Beemath A, Meyers FA, et al. Pulmonary embolism as a cause of death in patients who died with cancer. Am J Med. 2006;119(2): 163–165.
   PubMed Web of Science ®Google Scholar
• Smith JP, Conter RL, Demers LM, et al. Elevated levels of opioid growth factor in the plasma of patients with pancreatic cancer. Pancreas. 2000;21(2):158–164.
   Web of Science ®Google Scholar
• Zagon IS, Jaglowski JR, Verderame MF, et al. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2005;56(5):510–520.
   Web of Science ®Google Scholar